Kimyon, G. Et Al. 2021. Biological and targeted-synthetic disease-modifying anti-rheumatic drugs with concomitant methotrexate or leflunomide in rheumatoid arthritis: real-life TReasure prospective data.. Clinical and experimental rheumatology , vol.39, no.4 , 852-858.

Kimyon, G., Kalyoncu, U., Kiraz, S., Bes, C., Coşkun, N., Yağiz, B., ... Küçükşahin, O.(2021). Biological and targeted-synthetic disease-modifying anti-rheumatic drugs with concomitant methotrexate or leflunomide in rheumatoid arthritis: real-life TReasure prospective data.. Clinical and experimental rheumatology , vol.39, no.4, 852-858.

Kimyon, Gezmiş Et Al. "Biological and targeted-synthetic disease-modifying anti-rheumatic drugs with concomitant methotrexate or leflunomide in rheumatoid arthritis: real-life TReasure prospective data.," Clinical and experimental rheumatology , vol.39, no.4, 852-858, 2021

Kimyon, Gezmiş Et Al. "Biological and targeted-synthetic disease-modifying anti-rheumatic drugs with concomitant methotrexate or leflunomide in rheumatoid arthritis: real-life TReasure prospective data.." Clinical and experimental rheumatology , vol.39, no.4, pp.852-858, 2021

Kimyon, G. Et Al. (2021) . "Biological and targeted-synthetic disease-modifying anti-rheumatic drugs with concomitant methotrexate or leflunomide in rheumatoid arthritis: real-life TReasure prospective data.." Clinical and experimental rheumatology , vol.39, no.4, pp.852-858.

@article{article, author={Gezmiş Kimyon Et Al. }, title={Biological and targeted-synthetic disease-modifying anti-rheumatic drugs with concomitant methotrexate or leflunomide in rheumatoid arthritis: real-life TReasure prospective data.}, journal={Clinical and experimental rheumatology}, year=2021, pages={852-858} }